Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia

BioDrugs

Volumn 19, Issue 1, 2005, Pages 59-65

  Ibáñez, Cristina ^a   Suñé, Pilar ^a   Fierro, Ana ^a   Rodríguez, Santiago ^a   López, Maite ^b   Álvarez, Antonio ^a   De Gracia, Javier ^a   Montoro, José Bruno ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Instituto Grifols   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOBULIN S D; GAMMA INTERFERON; GAMMAGARD S D; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOMODULATION; INFLAMMATORY DISEASE; MALE; PRIORITY JOURNAL; SERUM;

ADULT; AGAMMAGLOBULINEMIA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON TYPE II; INTERLEUKINS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15944416765     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200519010-00007     Document Type: Article

References (27)

1. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109 (6): 1001-4
2. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000; 37 (3): 261-6
3. Latov N, Chaudhry V, Koski CL, et al. Use of intravenous gamma globulins in neuroimmunologic diseases. J Allergy Clin Immunol 2001; 108 (4): 126-32
4. Sato N, Sugimura T, Akagi T, et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 1999; 41 (1): 1-7
5. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000; 142: 551-4
6. Salmun L, Barlan I, Wolf H, et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 1999; 103 (5): 810-5
7. Winston DJ, Antin JH, Wolff SN, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogenic bone marrow transplantation. Bone Marrow Transplant 2001; 28 (2): 187-96
8. Andersson J, Skansén-Saphir U, Sparrelid E, et al. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 (Suppl. 1): 10-20
9. Toungouz M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-α production occurring during mixed lymphocyte reaction by interferon-γ-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996; 62 (9): 1292-6
10. Andersson UG, Björk L, Skansén-Saphir U. et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-6
11. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the control of complement action. Immunol Res 2000; 22 (2-3): 137-46
12. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998; 51 (Suppl. 5): 2-8
13. Kazatchkine M, Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345 (10): 747-55
14. Aukrust P, Müller F, Froland SS. Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes. Clin Immunol Immunopathol 1994; 70 (3): 217-24
15. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84 (7): 2136-43
16. Sharief MK, Ingram DA, Swash M, et al. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999; 52: 1833-8
17. Ling Z, Yeoh E, Webb BT, et al. Intravenous immunoglobulin induces interferon-γ and interleukin-6 in vivo. J Clin Immunol 1993; 13 (5): 302-9
18. Gupta M, Noel GJ, Schaefer M, et al. Cytokine modulation with immune γ-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21 (3): 193-9
19. Cooper N, Heddle NM, de Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcγRIIa and FcγRIIIa polymorphisms. Br J Haematol 2004; 124: 511-8
20. Aukrust P, Müller F, Svenson M, et al. Administration of intravenous immunoglobulin (IVIG) in vivo: down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999; 115: 136-43
21. Iglesias-Alzueta J, Matamoros-Flori N. Common variable immunodeficiency. Allergol Immunopathol (Madr) 2001; 29 (3): 113-8
22. Leung DY, Cotran RS, Kurt-Jones E, et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; II: 1298-302
23. Schindler R, Mancilla J, Endres S, et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-7
24. Mazzei GJ, Bernasconi LM, Lewis C, et al. Human granulocyte-macrophage colony-stimulating factor plus phorbol myristate acetate stimulate a promyelocytic cell line to produce an IL-1 inhibitor. J Immunol 1991; 145: 585-91
25. Aukrust P, Müller F, Nordoy I, et al. Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Clin Exp Immunol 1997; 107: 50-6
26. Huang JL, Lee WY, Chen LC, et al. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000; 84: 345-52
27. Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis, Blood 2002; 100 (5): 1774-9